Cyanokit is a drug owned by Btg International Inc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Nov 14, 2016. Details of Cyanokit's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5834448 | Dosage form of hydroxocobalamin and its use in cyanide poisoning |
Nov, 2016
(8 years ago) |
Expired
|
FDA has granted several exclusivities to Cyanokit. Till the time
these exclusivities
are active, no other company can market a generic or bioequivalent version of Cyanokit, regardless of the status of it's patents. These exclusivities hence play a crucial role in
delaying the generic
launch. Given below are details of the exclusivities granted to
Cyanokit.
Exclusivity Information
Cyanokit holds 1 exclusivities. All of its exclusivities have expired in 2013. Details of Cyanokit's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Dec 15, 2013 |
US patents provide insights into the exclusivity only within the United States, but
Cyanokit is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Cyanokit's family patents as well as insights into
ongoing legal events
on those patents.
Cyanokit's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Cyanokit's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Nov 14, 2016 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Cyanokit Generic API suppliers:
Hydroxocobalamin is the generic name for the brand Cyanokit. 5 different companies have already filed for the generic of Cyanokit, with Abraxis Pharm having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Cyanokit's generic
About Cyanokit
Cyanokit is a drug owned by Btg International Inc. It is used for the treatment of cyanide poisoning. Cyanokit uses Hydroxocobalamin as an active ingredient. Cyanokit was launched by Btg Intl in 2006.
Approval Date:
Cyanokit was approved by FDA for market use on 15 December, 2006.
Active Ingredient:
Cyanokit uses Hydroxocobalamin as the active ingredient. Check out other Drugs and Companies using Hydroxocobalamin ingredient
Treatment:
Cyanokit is used for the treatment of cyanide poisoning.
Dosage:
Cyanokit is available in injectable form for injection use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 2.5GM/VIAL (5GM/KIT) | INJECTABLE | Discontinued | INJECTION |
| 5GM/VIAL (5GM/KIT) | INJECTABLE | Prescription | INJECTION |